E-DRUG: Questions on ARVs
-------------------------
Sir/Madam I have the following queries:
1) Trizir (combination of Abacavir, Lamivudine and AZT) is registered in
several countries. All of the ingredients are NRTI. I would like to know in
which cases Trizir is recommended for use?. I understand that HAART is
supposed to be composed of ARVs from different groups.
2) Is there a danger of resistance emergence when using monotherapy for
PMTCT e.g. AZT or nevirapine? is there a recommendation of using triple
therapy in this case?
3) PEP: Treatment with antiretroviral drugs may be appropriate following
occupational exposure to HIV-contaminated material (within 48 hours of
exposure). can this PEP recommenddation be applicable when someone do
unprotected sex (with HIV+ person).
I will appreciate your reply
Mwemezi Ngemera
TADATIS
Tanzania
tadatis@simbanet.net
[E-drug gets more and more basic questions like these on proper use of ARVs.
Obviously someone should send Mwemezi a sound answer (TADATIS is the Drug
Information Centre in the Tanzanian Drug regulatory Authority), but maybe as
a community we can collect a few critical websites with trusted ARV
information?
May I start recommending the WHO and UNAIDS websites?
www.who.int/hiv
www.unaids.org
Is there already a Tanzania based website on AIDS and ART?
The following issues would also benefit from a good review in E-drug:
- WHO recommendations include ABC but maybe recent findings are less
positive about ABC?
- use of NVP in MTCT and risk of resistance (recent S.Francisco conference
data)?
- does PEP work for unprotected sex?
Any E-drug volunteers?
WB]
--
To send a message to E-Drug, write to: e-drug@healthnet.org
To subscribe or unsubscribe, write to: majordomo@healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: e-drug-help@healthnet.org
Information and archives: http://www.essentialdrugs.org/edrug